Medical/Pharmaceuticals
Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
SHANGHAI, April 22, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC (bulumtatug fuvedotin, R&D code: 9MW2821) for the treatment ...
2026-04-22 08:00
6423
Dawn Medical Technologies Acquires Controlling Interest in Pinnacle Health in Vietnam
* Strategic entry into high-growth Vietnam market * Combines Dawn's product sourcing capabilities with Pinnacle Health's established local presence and market expertise * Advances Dawn's mission to expand access to high-quality, affordable medical technologies across Southeast Asia SINGAPORE...
2026-04-22 08:00
5759
ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026
Phase 2 study of EBV-specific T cell therapy to be presented at a leading oncology meeting SEOUL, South Korea, April 21, 2026 /PRNewswire/ -- ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on advanced cell therapies, today announced that resu...
2026-04-22 07:30
3498
Dimora Medical Goes Viral on TikTok, as Hydrocolloid Roll Finds New Use in Acne Care
NEW YORK, April 21, 2026 /PRNewswire/ -- Over the past 28 days, Dimora Medical
2026-04-22 01:50
5998
Keung To Appointed Official Brand Ambassador for Herbalgy and Touch Cool
KEEP ME UP. HOLD TIGHT. KEEP GOING.
Limited-Edition Collectible Keychains Drop Now
Your Bag, Your Keys, Your Everyday
Download high-resolution images: https://bit.ly/4tw4GyF
2026-04-21 21:30
4942
ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT
An isogenic iPSC and AI-enabled disease modeling platform spanning multiple genetically defined CMT subtypes will be established to support patient stratification, accelerate RTX-117 development, and create a shared foundation for next-generation therapies BRISBANE, Calif., April 21, 2026 /PRNew...
2026-04-21 21:11
3801
Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery
CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the strategic formation of the industry's first Longevity Board (Board). The initiative provides scienti...
2026-04-21 21:05
6158
Getinge Interim Report January-March 2026: Organic growth, strong cash flow and regulatory milestone
GOTHENBURG, Sweden, April 21, 2026 /PRNewswire/ -- "We succeeded in surpassing last year's record-breaking first quarter with organic growth in both net sales and order intake," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased organically by 0.8% while th...
2026-04-21 20:36
3272
HKeybio Launches World's First NHP Hidradenitis Suppurativa Model with High Clinical Consistency to Tackle Global Drug R&D Bottleneck
BOSTON and SUZHOU, China, April 21, 2026 /PRNewswire/ -- HKeybio Tech., a global leader in non-human primate (NHP) experimental animal model research and development, today announced the official launch of theworld's first NHP Hidradenitis Suppurativa (HS) model, based on over ten years of resear...
2026-04-21 20:30
4884
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
* Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyyb) * Findings emphasize clinical decision-making in long-term management of inflammatory bo...
2026-04-21 20:00
5774
Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety t...
2026-04-21 20:00
3328
From Molecular Design to Scalable Execution: The Combined Impact of AI and Flow Chemistry
SHANGHAI, April 21, 2026 /PRNewswire/ -- As drug discovery places greater emphasis on practical execution and scalable delivery, flow chemistry is playing an increasingly important role across modern synthesis workflows. At the latest Viva Biotech's series webinar, "AI x Flow Chemistry: From Benc...
2026-04-21 17:57
5732
Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
HONG KONG, April 20, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line treatme...
2026-04-21 10:54
4936
Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile
– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed) – mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23% – No Grade 3 or higher adverse events related to RZ-001 observed – Highlights clinical potential of RNA trans-splicing ribozyme platform technology SEOUL, South...
2026-04-21 10:10
3997
Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time
SHANGHAI, April 21, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-mab, has successfully passed the on-site GMP inspection conducted by the Jordan Food and Drug Adminis...
2026-04-21 10:00
5771
AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data we...
2026-04-20 22:00
4739
Datasea Intelligent Technology Ltd. Completes Delivery of Three AI Multimodal Solution Projects with Aggregate Contract Value of Approximately USD 1.01 Million
Completed Projects Further Support the Company's Transition Toward High-Margin, Solution-Driven Revenue and Strengthen Customer Stickiness Across AI Multimodal Application Scenarios BEIJING, April 20, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Comp...
2026-04-20 21:15
7100
Seegene Introduces STAgora at ESCMID Global 2026, Highlighting Real-Time Data with Automated PCR Workflows
* The company highlights its approach to integrating real-time data analytics with automated PCR infrastructure * The standalone booth features STAgora simulation and an interactive touchscreen experience * An enhanced CURECA model is presented, illustrating next-generation automated labora...
2026-04-20 21:00
4828
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
* With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner * Advancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions ...
2026-04-20 19:30
3243
Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026
SHANGHAI, April 20, 2026 /PRNewswire/ -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myelom...
2026-04-20 18:45
3955
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 307 media titles]
2026-10-27 13:40
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 296 media titles]
2026-10-22 22:35
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 281 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 278 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
36572
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
35733
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
34483
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
28871
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
17778
